How to Handle Volcanic Ash?

Iceland's Eyjafjallajokull volcano brought air transport to a halt in much of Europe for nearly a week. And now there are questions over whether the European air ministries over-reacted. What do you think? If you were a passenger needing to fly, would you want the authorities permitting flights or e

Are We All on the Same Wavelength?

Technology is rapidly changing healthcare delivery. Connected patients are being empowered to take a more active role in their health and fitness. Remote patient monitoring can lower the cost of patient care while ensuring that a patient is never really out of range of medical care. Device interoper

SDO opens its eyes and sees our star like never before | Bad Astronomy

Last week, NASA presented the first images and videos from its latest and greatest eye on the Sun: the Solar Dynamics Observatory.

SDO has been in the works for a long, long time, and I’ve been anxiously awaiting data from it for years… so of course I was away from my computer when the images were released. Still, it was worth a few extra days to see something as back-of-the-neck-hair-raising as this:

sdo_prominence

Holy Haleakala! Click to emprominate.

As if on cue, just days after SDO’s Atmospheric Imaging Assembly (AIA) was switched on, the Sun threw an epic fit, blasting out an arcing prominence perfectly positioned for us to see. A prominence is a loop of gas that erupts from the surface of the Sun. This gas follows the Sun’s magnetic field lines; complicated interplay between the energy stored in the field lines versus their tension causes them to leap up from the Sun, anchored in two spots that represent where the north and south poles of the lines punch through the Sun’s surface. A prominence might have as much as a hundred billion tons of matter in it, and can be hundreds of thousands of kilometers across.

To give you an idea of this, here’s a video made from images from AIA:

Kaboom! Interestingly, the gas isn’t as hot as you might think, and can be cooler than the surface of the Sun. When we see a prominence edge-on, silhouetted against the surface of the Sun, it actually appears dark! When that happens, we call it a filament.

I’ve been a big fan of the Solar and Heliospheric Observatory (SOHO) for a long time, and SDO is like the Son of SOHO. It has technology that is more current, and has very high resolution cameras. SDO can take spectra of the Sun to look in detail at its composition, temperature, motion, and magnetic strength. It can also measure the seismology of the surface of the Sun, the way waves travel across it and make it pulse; this tells us about the interior of the Sun that is otherwise totally invisible. Combining all this data together yields a vast amount of knowledge waiting to be learned about our nearest star.

It also produces stunning full-Sun imagery:

sdo_composite_fullsun

This image is amazing; it shows very hot helium and iron ranging in temperature from 60,000 Kelvin (100,000+° F) to well over a million Kelvins (1.8 million degrees F)! You can see the big prominence to the left, as well as several others around the disk. All the twisting and writhing on the surface is due to the bubbling convection of hot material from the Sun’s interior rising to the surface coupled with the fiercely complex solar magnetic field. The physics involved is incredibly complex, but with SDO’s help scientists will soon have a much firmer grasp on what’s going on.

Of course, they’ll also have a pile of new mysteries to ponder as well. The Sun is the closest star to the Earth, and closer than most planets. We know a lot about it, but there’s so much left to understand: what’s the root cause of the 5.5 year long solar magnetic cycle? How is that tied to Earth’s climate? What effect do sunspots have on the Sun and Earth? How exactly does the Sun influence space weather; the flood of subatomic particles streaming from the solar surface and interacting with our own magnetic field, affecting satellites and even our power grid?

Science is like a tapestry with no edge, and with holes located here and there in the fabric. We can fill those holes ever more, and explore the edges, pushing them back with each new discovery. Along with many other observatories like it, SDO is our loom that helps us create and follow that weave.

Credit: NASA/SDO/AIA, NASA/GSFC/SDO/AIA


How To Make A 3G Router

From Gizmodo:

Bought a Chumby One and aren't sure what to do with it? Turn the device into a 3G router! It's quick and you'll need nothing but a Chumby One, a 3G USB modem, and these instructions.

Read the whole article

Portable Dimmer Circuit Fuse Rating

I Have taken over a project delivering a 2000 watt dimmer circuit. I am a little confused on how the previous person built the circuit. The circuit consist of a 12/3 power cord (NEMA 5-15P)connected inline with a GFCI (faceless) , this is then connected to a 2000 W dimmer switch and then to a exit c

Genomes May One Day Be Medical Crystal Balls

From NPR Topics: News:

Stanford scientist Steve Quake was only the fifth person in the world to have his entire genome spelled out. Now he claims to be the first to use it to find out just what diseases he's at risk for and what he should do about it. What Quake and his doctor lear

NASA Balloon Crashes On Liftoff

NASA Balloon Suffers Mishap in Australia, NASA

"Upon release, the balloon's payload hit the ground and was dragged approximately 150 yards before hitting a fence and sports utility vehicle. No one was injured. A mishap investigation board is being convened."

NASA balloon crashes on take-off in Australia, destroying telescope, USA Today

"A towering NASA science balloon bearing a gamma-ray telescope crashed on liftoff today in Australia, according to reports from the Outback. The gondola carrying the multimillion-dollar package overturned an SUV and narrowly missed several onlookers. The Nuclear Compton Telescope, which was developed by the University of California, was destroyed. The telescope "came off the launch vehicle badly and hit the ground several times as the abort completed," team member Eric Bellm, a graduate astronomy student at the UC-Berkeley, wrote on the mission's blog [now blocked]."

Alternative Material to SB:L73

Hi everyone, I'm supposed to manufacture a part in Alclad L73 (British Standard aluminium alloy), does anyone know an alternative material to it? Does somebody knows where to find its mechanical properties (of L73)? Thanks, PireX

European man perhaps not a Middle Eastern farmer | Gene Expression

A few months ago I blogged a paper in PLoS Biology which suggested that a common Y chromosomal haplogroup, in fact the most common in Europe and at modal frequency along the Atlantic fringe, is not pre-Neolithic. Rather their analysis of the data implied that the European variants were derived from an Anatolian variant. The implication was that a haplogroup which had previously been diagnostic of “Paleolithicness,” so to speak, of a particular population may in fact be an indication of the proportion of Neolithic Middle Eastern ancestry. The most interesting case were the Basques, who have a high frequency of this haplogroup, and are often conceived of as “ur-Europeans,” Paleolithic descendants of the Cro-Magnons in the most romantic tellings. I was somewhat primed to accept this finding because of confusing results from ancient DNA extraction which implies a lot of turnover in maternal lineages, the mtDNA. My logic being that if the mtDNA exhibited rupture, then the Y lineages should too, as demographic revolutions are more likely to occur among men.

But perhaps not. A new paper in PLoS ONE takes full aim at the paper I blogged above. It is in short a purported refutation of the main finding of the previous paper, and a reinstatement of what had been the orthodoxy (note the citations to previous papers). A Comparison of Y-Chromosome Variation in Sardinia and Anatolia Is More Consistent with Cultural Rather than Demic Diffusion of Agriculture:

Two alternative models have been proposed to explain the spread of agriculture in Europe during the Neolithic period. The demic diffusion model postulates the spreading of farmers from the Middle East along a Southeast to Northeast axis. Conversely, the cultural diffusion model assumes transmission of agricultural techniques without substantial movements of people. Support for the demic model derives largely from the observation of frequency gradients among some genetic variants, in particular haplogroups defined by single nucleotide polymorphisms (SNPs) in the Y-chromosome. A recent network analysis of the R-M269 Y chromosome lineage has purportedly corroborated Neolithic expansion from Anatolia, the site of diffusion of agriculture. However, the data are still controversial and the analyses so far performed are prone to a number of biases. In the present study we show that the addition of a single marker, DYSA7.2, dramatically changes the shape of the R-M269 network into a topology showing a clear Western-Eastern dichotomy not consistent with a radial diffusion of people from the Middle East. We have also assessed other Y-chromosome haplogroups proposed to be markers of the Neolithic diffusion of farmers and compared their intra-lineage variation—defined by short tandem repeats (STRs)—in Anatolia and in Sardinia, the only Western population where these lineages are present at appreciable frequencies and where there is substantial archaeological and genetic evidence of pre-Neolithic human occupation. The data indicate that Sardinia does not contain a subset of the variability present in Anatolia and that the shared variability between these populations is best explained by an earlier, pre-Neolithic dispersal of haplogroups from a common ancestral gene pool. Overall, these results are consistent with the cultural diffusion and do not support the demic model of agriculture diffusion.

Their main trump cards seem to be that they used a denser set of markers, and, they claim they have a more accurate molecular clock. Ergo, in the latter case they produce a better time to the last common ancestor, which is twice as deep as the paper they’re attempting to refute. Someone like Dienekes or Polish Genetics can tackle the controversies in scientific genealogy here (I know Dienekes has a lot of interest in mutational rates which go into the molecular clock for these coalescence times). Rather, I would suggest that usage of Sardinians concerns me for an obvious reason: they’re genetic outliers in Europe. A lot of this has to do with being an island. Islands build up uniqueness because they don’t engage in the normal low level gene flow between adjacent populations because they’re…well, islands. You would know about Sardinia’s position because they’re one of the populations in L. L. Cavalli-Sforza’s HGDP sample and they show up in History & Geography of Human Genes as on the margins of the PCA plots. But here’s a figure from a more recent paper using a much denser market set, constrained to Southern European populations. I labelled some of the main ones so you’d get a sense of why I say Sardinians are outliers:
sardin

Over the two largest independent dimensions of genetic variation you can see a distribution from the southeast Mediterranean all the way to the northwest (in fact, the Basques are an Atlantic group). The Sardinians are out of the primary axis, and that’s why I say they’re an outlier. A few other European groups, like the Icelanders and Sami exhibit this tendency. As I suggested above I think the fact that the Sardinians are on an isolated island relatively far from the European and Africa mainland means that they’ll “random walk” in genetic variation space toward an outlier status naturally, just as the Icelanders have since the year 1000. So though I grant the authors their rationale for using the Sardinians as a reference against the Anatolian source population, the fact that we know that they’re peculiar in their variation in total genome content makes me wary of drawing too many inferences from their relationships to other groups where they are seen as representative of a larger set.

Citation: Morelli L, Contu D, Santoni F, Whalen MB, & Francalacci P (2010). A Comparison of Y-Chromosome Variation in Sardinia and Anatolia Is More Consistent with Cultural Rather than Demic Diffusion of Agriculture PLoS ONE : 10.1371/journal.pone.0010419

On Attacking Cancer Stem Cells

This EurekAlert! release looks at some of the challenges facing the increasing number of research groups who are attempting to destroy cancer stem cells: "Many of the colon cancer cells that form tumors can be killed by genetically short-circuiting the cells' ability to absorb a key nutrient, a new study has found. While the findings are encouraging, the test tube study using human colon cancer cells also illustrates the difficulty of defeating these cells, known as cancer stem cells (CSCs). ... It is becoming more evident that only a small number of cells in the tumor are capable of forming the tumor, namely the cancer stem cell. So the new strategy is to eliminate the cancer stem cells and thus lower the recurrence of cancer. ... Because CSCs have properties similar to normal stem cells, we have to find a way to attack them while keeping the adult stem cells alive. ... To do that, the research team inactivated a receptor that is found in increased amounts in colon cancer cells: the insulin-like growth factor receptor (IGF-1R). The colon cancer CSCs seem to need a fair amount of IGF to live, more than other cells, and they can't function without the IGF receptor. ... Working with human colon cancer cells, the researchers manipulated the cellular genetics using small interfering RNA (siRNA) to prevent the synthesis of IGF-1R. In this way, they reduced the number of IGF receptors by half, and reduced the number of CSCs by 35%."

View the Article Under Discussion: http://www.eurekalert.org/pub_releases/2010-04/foas-ras042210.php

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

On the Pope’s Opposition to Engineered Longevity

From TechNewsWorld: "During his homily this Easter, Pope Benedict argued that medical science, in trying to defeat death, is leading humanity toward likely condemnation. It's a position at odds with the value of life, one that the Church will likely revise years from now, replaying the institution's embarrassment over censoring Galileo. ... If scientists are successful in finding techniques to rebuild cartilage, repair organs, and cure cancer, people will indeed be living longer - but they will also be healthier, more energetic and youthful. Health-extension, when it happens, will allow people to live longer, better. Consider that 60-year-olds today are not in the same shape as their counterparts were in the 1800s or 1900s. As humans discovered how to take better care of themselves, through improved nutrition, the use of antibiotics and other techniques, 'chronological age' became less synonymous with 'biological age.' That is, many of today's 60-year-olds act and feel much younger than one might expect. The average human life expectancy today is close to 80 years but in 1850, it was 43 years, and in 1900 it was 48 years. One can imagine someone in 1850 arguing that doubling life expectancy would be terrible, because innovation might be at risk and there would be more old people around. But would anyone today say they are sorry that science made it possible to live longer and healthier lives?"

View the Article Under Discussion: http://www.technewsworld.com/story/Galileo-20-Here-Comes-Another-Apology-69876.html

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

On the Pope's Opposition to Engineered Longevity

From TechNewsWorld: "During his homily this Easter, Pope Benedict argued that medical science, in trying to defeat death, is leading humanity toward likely condemnation. It's a position at odds with the value of life, one that the Church will likely revise years from now, replaying the institution's embarrassment over censoring Galileo. ... If scientists are successful in finding techniques to rebuild cartilage, repair organs, and cure cancer, people will indeed be living longer - but they will also be healthier, more energetic and youthful. Health-extension, when it happens, will allow people to live longer, better. Consider that 60-year-olds today are not in the same shape as their counterparts were in the 1800s or 1900s. As humans discovered how to take better care of themselves, through improved nutrition, the use of antibiotics and other techniques, 'chronological age' became less synonymous with 'biological age.' That is, many of today's 60-year-olds act and feel much younger than one might expect. The average human life expectancy today is close to 80 years but in 1850, it was 43 years, and in 1900 it was 48 years. One can imagine someone in 1850 arguing that doubling life expectancy would be terrible, because innovation might be at risk and there would be more old people around. But would anyone today say they are sorry that science made it possible to live longer and healthier lives?"

View the Article Under Discussion: http://www.technewsworld.com/story/Galileo-20-Here-Comes-Another-Apology-69876.html

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

Latest Cell Therapy Approval by FDA. Dendreon’s Provenge.

It has been a long-time coming. It has been hyped and scoffed, bet against and hoped for, but now none of that matters. It's here. Dendreon has brought Provenge to market. Here, in the word's of the FDA...

FDA NEWS RELEASE

For Immediate Release: April 29, 2010

FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. In 2009, an estimated 192,000 new cases of prostate cancer were diagnosed and about 27,000 men died from the disease, according to the National Cancer Institute.

“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.

Provenge is an autologous cellular immunotherapy, designed to stimulate a patient’s own immune system to respond against the cancer. Each dose of Provenge is manufactured by obtaining a patient’s immune cells from the blood, using a machine in a process known as leukapheresis. To enhance their response against the cancer, the immune cells are then exposed to a protein that is found in most prostate cancers, linked to an immune stimulating substance. After this process, the patient’s own cells are returned to the patient to treat the prostate cancer. Provenge is administered intravenously in a three-dose schedule given at about two-week intervals.

The effectiveness of Provenge was studied in 512 patients with metastatic hormone treatment refractory prostate cancer in a randomized, double-blind, placebo-controlled, multicenter trial, which showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment.

Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions reported included chills, fatigue, fever, back pain, nausea, joint ache and headache. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in approximately one quarter of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 percent of patients in the Provenge group compared with 2.6 percent of patients in the control group.

Provenge is manufactured by Seattle-based Dendreon Corp.

Latest Cell Therapy Approval by FDA. Dendreon's Provenge.

It has been a long-time coming. It has been hyped and scoffed, bet against and hoped for, but now none of that matters. It's here. Dendreon has brought Provenge to market. Here, in the word's of the FDA...

FDA NEWS RELEASE

For Immediate Release: April 29, 2010

FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. In 2009, an estimated 192,000 new cases of prostate cancer were diagnosed and about 27,000 men died from the disease, according to the National Cancer Institute.

“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.

Provenge is an autologous cellular immunotherapy, designed to stimulate a patient’s own immune system to respond against the cancer. Each dose of Provenge is manufactured by obtaining a patient’s immune cells from the blood, using a machine in a process known as leukapheresis. To enhance their response against the cancer, the immune cells are then exposed to a protein that is found in most prostate cancers, linked to an immune stimulating substance. After this process, the patient’s own cells are returned to the patient to treat the prostate cancer. Provenge is administered intravenously in a three-dose schedule given at about two-week intervals.

The effectiveness of Provenge was studied in 512 patients with metastatic hormone treatment refractory prostate cancer in a randomized, double-blind, placebo-controlled, multicenter trial, which showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment.

Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions reported included chills, fatigue, fever, back pain, nausea, joint ache and headache. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in approximately one quarter of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 percent of patients in the Provenge group compared with 2.6 percent of patients in the control group.

Provenge is manufactured by Seattle-based Dendreon Corp.